Upload
phamhuong
View
214
Download
0
Embed Size (px)
Citation preview
2:15 65%
100
200
300
400
401 PM 12 PM
102mg/dL
102mg/dL
102mg/dL
102mg/dL
17x22 poster
2:15 65%
100
200
300
400
401 PM 12 PM
102mg/dLmg/dL102102 mg/dL
400
300250
150200
100
350
2:15 PM12 PM11 AM 1 PM
1
2
3
12
3
A1C
+–
24hours/day
UP TO 288 READ
ING
S A DAY
EVERY 5 M
INU
TES
References1 Dexcom G5 Mobile CGM System User Guide. 2 2015 AACE/ACE Guidelines. Endocr Pract. 2015; 21. Vol 21 (5) pg. 522-533. 3 Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Continuous Glucose Monitoring and Intensive Treatment of Type 1 Diabetes, N Engl J Med. 2008: 359(14); 1464-1476. 4 Choudhary P, Ramasamy S, Green L et al. Real-Time Continuous Glucose Monitoring Significantly Reduces Severe Hypoglycemia in Hypoglycemia-Unaware Patients With Type 1 Diabetes. Diabetes Care. 2013;36(12):4160-4162. 5 Battelino T, Phillip M, Bratina N, Nimri R, Oskarsson P, Bolinder J. Effect of continuous glucose monitoring on hypoglycemia in type 1 diabetes. Diabetes Care. 2011;34(4):795-800.
BRIEF SAFETY STATEMENT: The Dexcom G5 Mobile Continuous Glucose Monitoring System is a glucose monitoring system indicated for detecting trends and tracking patterns in persons (age 2 years and older) with diabetes. CONTRAINDICATIONS: Remove the System before MRI, CT scan, or diathermy treatment. The device is MR Unsafe. Do not bring any portion of the System into the MR environment. Taking acetaminophen while wearing the sensor may falsely raise your sensor glucose readings. WARNING: Do not use the System for treatment decisions. The System does not replace a blood glucose meter. The System is not approved for use in pregnant women, persons on dialysis or critically ill persons. If a sensor breaks and no portion of it is visible above the skin, do not attempt to remove it. Seek professional medical help if you have infection or inflammation. Report broken sensors to Dexcom Technical Support. Sensor placement is not approved for sites other than under the skin of the belly (ages 2 years and older) or upper buttocks (ages 2-17 years). Your smart device’s internal settings override your app settings. Accessory devices (like a smart watch) might override your smart device’s alert and notification settings. The Share feature must be turned “On” with an active internet connection to communicate glucose information to a Follower. The Follower must download and install the Dexcom Follow App onto a separate smart device with an active internet connection to receive data. Contact Dexcom Toll Free at 877-339-2664 or www.dexcom.com for detailed indications for use and safety information.
The web-based Dexcom CLARITY™ software is intended for use by both home users and healthcare professionals to assist people with diabetes in the review, analysis, and evaluation of historical CGM data to support effective diabetes management. It is intended for use as an accessory to CGM devices with data interface capabilities. Caution: The software should not be relied on for medical advice. Home users must consult a Healthcare Professional before making any medical interpretation and therapy adjustments from the information in these Reports. The software does not provide any medical advice and should not be used for that purpose. Healthcare professionals should use information form the software in conjunction with other clinical information available to them.
©2016 Dexcom, Inc. All rights reserved. LBL013927 Rev001
WHAT IS CGM?Continuous Glucose Monitoring
Continuous Glucose Monitoring is an FDA-approved system that displays dynamic
information about glucose direction and speed, giving users additional insight to help with
diabetes management.
SPEED
DIRECTION
BGM displays a
single number
CGM displays a number,
speed and direction
of glucose
NUMBER
Blood Glucose Meter (BGM) vs. CGM
CGM gives you more insight. With the additional information from CGM about glucose, speed and direction, a person may decide to eat a snack to avoid a hypoglycemic event††, whereas they may not have taken action based on the BGM reading alone. Daily activities including meals and exercise, and other factors such as illness can impact glucose levels. CGM data can reveal what’s happening between fingersticks.††Always use a BGM for treatment decisions
The Simplicity of CGM Easy Patient OnboardingYou prescribe CGM, and Dexcom will verify insurance coverage, and provide training, and more.
Dexcom CLARITY™ Quickly gain clinically relevant insights through this web-based tool, including estimated A1C, historic glycemic variability, and time in range. Assess key glycemic patterns and contributing factors.
Value to Your Practice• CGM usage can reduce your patients’ A1C
levels, leading to improved performance metrics such as HEDIS scores.
• Bill for patient training and interpretation.
Insurance Coverage• CGM is covered by 98% of commercial
insurance carriers.
AACE/ACE CGM GuidelinesThe 2015 AACE/ACE Consensus Statement on CGM2 recommends that:
• All patients with type 1 diabetes should use CGM
• CGM should be offered to all type 2 diabetes patients on multiple insulin injections, basal insulin, or sulfonylureas
• CGM should also be used in patients at risk for hypoglycemia and/or have hypoglycemia unawareness
Benefits to Patients Reduction of A1C without increasing risk for hypoglycemia3 (JDRF landmark trial)
Reduction of severe hypoglycemic incidents4 and time spent in hypoglycemia by 50%5
Support for nocturnal events: the built-in hypo alarm and customizable alerts can warn patients of dangerous events that may go unnoticed using BGM alone
The Dexcom G5® Mobile Continuous Glucose Monitoring System (CGM)1
The Dexcom G5 Mobile CGM System consists of three components:
Sensor: Measures interstitial glucose levels just underneath the skin.
Transmitter: Fastened on top of sensor; sends data wirelessly to a display device.
The Dexcom G5 Mobile CGM System is:
• Indicated for patients 2 years and older with diabetes.
• An adjunctive device and does not replace a blood glucose meter.
• Requires a prescription.SENSOR
TRANSMITTER
RECEIVER†
Display Device: Glucose data and trends can be displayed either on the Dexcom G5 Mobile Receiver or a compatible smart device.*
FrequentReadings
Data Sharing:Via the Dexcom G5 Mobile App,
users can share their glucose information with up to five
individuals for added support. (Requires the
Dexcom Follow App*)
Alerts & Alarms: Alerts including a built-in
hypo alarm (55 mg/dL)warn of glucose highs
and lows, allowing user to take appropriate
action.
FEATURES
COMPATIBLE SMART DEVICE*†
3
*For a list of compatible devices, visit www.dexcom.com/compatibility. †Dexcom Receiver is part of the System; smart device sold separately.
2:15 65%
100
200
300
400
401 PM 12 PM
102mg/dL
102mg/dL
102mg/dL
102mg/dL
17x22 poster
2:15 65%
100
200
300
400
401 PM 12 PM
102mg/dLmg/dL102102 mg/dL
400
300250
150200
100
350
2:15 PM12 PM11 AM 1 PM
1
2
3
12
3
A1C
+–
24hours/day
UP TO 288 READ
ING
S A DAY
EVERY 5 M
INU
TES
References1 Dexcom G5 Mobile CGM System User Guide. 2 2015 AACE/ACE Guidelines. Endocr Pract. 2015; 21. Vol 21 (5) pg. 522-533. 3 Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Continuous Glucose Monitoring and Intensive Treatment of Type 1 Diabetes, N Engl J Med. 2008: 359(14); 1464-1476. 4 Choudhary P, Ramasamy S, Green L et al. Real-Time Continuous Glucose Monitoring Significantly Reduces Severe Hypoglycemia in Hypoglycemia-Unaware Patients With Type 1 Diabetes. Diabetes Care. 2013;36(12):4160-4162. 5 Battelino T, Phillip M, Bratina N, Nimri R, Oskarsson P, Bolinder J. Effect of continuous glucose monitoring on hypoglycemia in type 1 diabetes. Diabetes Care. 2011;34(4):795-800.
BRIEF SAFETY STATEMENT: The Dexcom G5 Mobile Continuous Glucose Monitoring System is a glucose monitoring system indicated for detecting trends and tracking patterns in persons (age 2 years and older) with diabetes. CONTRAINDICATIONS: Remove the System before MRI, CT scan, or diathermy treatment. The device is MR Unsafe. Do not bring any portion of the System into the MR environment. Taking acetaminophen while wearing the sensor may falsely raise your sensor glucose readings. WARNING: Do not use the System for treatment decisions. The System does not replace a blood glucose meter. The System is not approved for use in pregnant women, persons on dialysis or critically ill persons. If a sensor breaks and no portion of it is visible above the skin, do not attempt to remove it. Seek professional medical help if you have infection or inflammation. Report broken sensors to Dexcom Technical Support. Sensor placement is not approved for sites other than under the skin of the belly (ages 2 years and older) or upper buttocks (ages 2-17 years). Your smart device’s internal settings override your app settings. Accessory devices (like a smart watch) might override your smart device’s alert and notification settings. The Share feature must be turned “On” with an active internet connection to communicate glucose information to a Follower. The Follower must download and install the Dexcom Follow App onto a separate smart device with an active internet connection to receive data. Contact Dexcom Toll Free at 877-339-2664 or www.dexcom.com for detailed indications for use and safety information.
The web-based Dexcom CLARITY™ software is intended for use by both home users and healthcare professionals to assist people with diabetes in the review, analysis, and evaluation of historical CGM data to support effective diabetes management. It is intended for use as an accessory to CGM devices with data interface capabilities. Caution: The software should not be relied on for medical advice. Home users must consult a Healthcare Professional before making any medical interpretation and therapy adjustments from the information in these Reports. The software does not provide any medical advice and should not be used for that purpose. Healthcare professionals should use information form the software in conjunction with other clinical information available to them.
©2016 Dexcom, Inc. All rights reserved. LBL013927 Rev001
WHAT IS CGM?Continuous Glucose Monitoring
Continuous Glucose Monitoring is an FDA-approved system that displays dynamic
information about glucose direction and speed, giving users additional insight to help with
diabetes management.
SPEED
DIRECTION
BGM displays a
single number
CGM displays a number,
speed and direction
of glucose
NUMBER
Blood Glucose Meter (BGM) vs. CGM
CGM gives you more insight. With the additional information from CGM about glucose, speed and direction, a person may decide to eat a snack to avoid a hypoglycemic event††, whereas they may not have taken action based on the BGM reading alone. Daily activities including meals and exercise, and other factors such as illness can impact glucose levels. CGM data can reveal what’s happening between fingersticks.††Always use a BGM for treatment decisions
The Simplicity of
Easy Patient OnboardingYou prescribe CGM, and Dexcom will verify insurance coverage, and provide training, and more.
Dexcom CLARITY™ Quickly gain clinically relevant insights through this web-based tool, including estimated A1C, historic glycemic variability, and time in range. Assess key glycemic patterns and contributing factors.
Value to Your Practice• CGM usage can reduce your patients’ A1C
levels, leading to improved performance metrics such as HEDIS scores.
• Bill for patient training and interpretation.
Insurance Coverage• CGM is covered by 98% of commercial
insurance carriers.
AACE/ACE CGM GuidelinesThe 2015 AACE/ACE Consensus Statement on CGM2 recommends that:
• All patients with type 1 diabetes should use CGM
• CGM should be offered to all type 2 diabetes patients on multiple insulin injections, basal insulin, or sulfonylureas
• CGM should also be used in patients at risk for hypoglycemia and/or have hypoglycemia unawareness
Benefits to Patients Reduction of A1C without increasing risk for hypoglycemia3 (JDRF landmark trial)
Reduction of severe hypoglycemic incidents4 and time spent in hypoglycemia by 50%5
Support for nocturnal events: the built-in hypo alarm and customizable alerts can warn patients of dangerous events that may go unnoticed using BGM alone
The Dexcom G5® Mobile Continuous Glucose Monitoring System (CGM)1
The Dexcom G5 Mobile CGM System consists of three components:
Sensor: Measures interstitial glucose levels just underneath the skin.
Transmitter: Fastened on top of sensor; sends data wirelessly to a display device.
The Dexcom G5 Mobile CGM System is:
• Indicated for patients 2 years and older with diabetes.
• An adjunctive device and does not replace a blood glucose meter.
• Requires a prescription.SENSOR
TRANSMITTER
RECEIVER†
Display Device: Glucose data and trends can be displayed either on the Dexcom G5 Mobile Receiver or a compatible smart device.*
FrequentReadings
Data Sharing:Via the Dexcom G5 Mobile App,
users can share their glucose information with up to five
individuals for added support. (Requires the
Dexcom Follow App*)
Alerts & Alarms: Alerts including a built-in
hypo alarm (55 mg/dL)warn of glucose highs
and lows, allowing user to take appropriate
action.
FEATURES
COMPATIBLE SMART DEVICE*†
3
*For a list of compatible devices, visit www.dexcom.com/compatibility. †Dexcom Receiver is part of the System; smart device sold separately.